FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M

First Page		Document Content
Date: 2016-04-19 06:39:33 Clinical medicine Medicine Lung cancer Biology KRAS Non-small-cell lung carcinoma Biomarker Ras subfamily FASN Fatty acid synthase		FASN inhibitor TVB-2640 shows pharmacodynamic effect and evidence of clinical activity in KRAS mutant NSCLC patients in a Phase 1 study Marie O’Farrell, Tim Heuer, Katharine Grimmer, Richard Crowley, Joanna Waszczuk, M Add to Reading List Source URL: www.3vbio.com Download Document from Source Website File Size: 997,69 KB Share Document on Facebook

	Neuroendocrinology Letters Volume 33 SupplComparison of gene expression of epicardial and visceral adipocytes with regard to the differentiation stage Institute for Clinical and Experimental Medicine, Departmen DocID: 1vq9m - View Document
	Policy Perspective - A Conversation with Peter Banys, MD, MSc Dr. Peter Banys is a Clinical Professor of Psychiatry at UCSF and Past-President of the California Society of Addiction Medicine. Over a three decade career h DocID: 1vgR8 - View Document
	Responsible Conduct of Research Data Susan Porter Clinical Associate Professor, Department of Pathology & Laboratory Medicine DocID: 1vcR1 - View Document
	1/3 2nd EurOPDX Workshop PDX models in clinical oncology and cancer precision medicine Seminar-Hotel Rigi am See DocID: 1v75r - View Document
	Centre for Cell Therapy and Regenerative Medicine 6th Margaret River Region Forum and 9th ASSCR Annual Scientific Meeting Stem Cells: Fundamental Biology and Clinical Translation DocID: 1v4Rh - View Document